18 and older, any sex, with Respiratory Syncytial Virus (RSV). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis SetPrimary· Up to 7 days
Group
Value
95% CI
Presatovir
-0.73
± 0.938
Placebo
-0.90
± 0.815
Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in a Subset of Participants in the Full Analysis Set Whose Duration of RSV Symptoms Prior to the First Dose of Study Drug is ≤ MedianPrimary· Up to 7 days
Group
Value
95% CI
Presatovir
-0.83
± 1.013
Placebo
-0.83
± 0.757
Time-Weighted Average Change in FLU-PRO Score From Day 1/Baseline Through Day 7Secondary· Up to 7 days
The Flu-PRO is a patient-reported outcome questionnaire utilized as a standardized method for evaluating symptoms of influenza. Flu-PRO Score was calculated as the mean of 38 individual scores. Individual scores ranged from 0 (no symptoms) to 4 (worst symptoms) for the 5-point severity scale and 0 (never) to 4 or more times (always) for the 5-point frequency scale. The mean values presented were calculated using the ANCOVA model and are adjusted for baseline value and stratification factor.
Group
Value
95% CI
Presatovir
-0.27
± 0.313
Placebo
-0.31
± 0.298
Percent Change From Study Baseline in FEV1% Predicted ValueSecondary· Baseline; Day 28
FEV1 is defined as forced expiratory volume in the first second.
Group
Value
95% CI
Presatovir
22.69
± 27.437
Placebo
26.36
± 23.312
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline up to Day 28.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The primary objective of this study is to evaluate the effect of presatovir on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT02254421 — Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Res
· Phase 2
· completed
NCT02254408 — Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respirato
· Phase 2
· completed
NCT02135614 — Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infec
· Phase 2
· completed
Other recruiting trials for Respiratory Syncytial Virus (RSV)
Currently open trials in the same condition.
NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
· recruiting
NCT06851806 — Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
· NA
· recruiting
NCT07249320 — Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
· active not recruiting
NCT07272434 — Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
· Phase 3
· recruiting
NCT07106918 — A Clinical Trial of SIBP-A16 Injection in Healthy Adults
· EARLY_PHASE1
· recruiting
Other Gilead Sciences trials
Trials by the same sponsor.
NCT07115368 — Study of GS-1219 in Participants With HIV-1
· Phase 1
· terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
· Phase 2
· terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain
· completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
· Phase 2, PHASE3
· terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
· Phase 2
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 28 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02534350.